PEPTIDE CORTEXThe library
← The library

Survodutide

researchMetabolic/Weight
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
2
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight
MechanismDual GLP-1 and glucagon receptor agonist in Phase 3 development
EffectsProduced 16.6% weight loss at 76 weeks in Phase 3; also studied in MASH
DosingTrial doses (not approved): phase 2 arms of 0.6, 2.4, 3.6 or 4.8 mg once weekly after a 20-week escalation; phase 3 SYNCHRONIZE-1 arms of up to 3.6 mg or up to 6.0 mg once weekly.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialPhase 2 (le Roux, Lancet Diabetes Endocrinol 2024)
RouteSubcutaneous injection
FrequencyOnce weekly, 46 weeks
StartingNot given in the abstract
Escalation20 weeks dose escalation; step sizes not in the abstract
TargetArms: 0.6, 2.4, 3.6 or 4.8 mg once weekly, 26 weeks maintenance. Weight change -6.2% to -14.9% vs -2.8% placebo.

GI adverse events 75% vs 42% placebo; only 61% completed treatment.

Clinical trialPhase 3 SYNCHRONIZE-1 (NEJM 2026)
RouteSubcutaneous injection
FrequencyOnce weekly, 76 weeks
StartingEscalation schedule not retrieved
EscalationDose adjusted up to the arm maximum; schedule not retrieved
TargetUp to 3.6 mg or up to 6.0 mg once weekly. Primary result (treatment-regimen estimand): body weight -12% (3.6 mg) and -13% (6.0 mg) vs -5% placebo at week 76. On the efficacy estimand, weight loss up to 16.6% vs 3.2% placebo.
Maximum6.0 mg weekly (maximum studied)
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous injection
FrequencyOnce weekly
Starting"Phase 2 trial began at 0.6 mg weekly"
Escalation"20-week escalation" in phase 2; phase 3 was "slower and more flexible"
Target2.4-3.6 mg
Cycle46 weeks (phase 2); 76 weeks (phase 3)

The guide's stated maximum is out of date and is not shown; phase 3 tested 6.0 mg.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 2 of 5 — Phase 3 weight and liver data are strong, but no cardiovascular outcomes trial has reported and it is not approved anywhere.